{"id":"eculizumab-soliris","safety":{"commonSideEffects":[{"rate":null,"effect":"Meningococcal infection"},{"rate":"30–40","effect":"Headache"},{"rate":"20–30","effect":"Nausea"},{"rate":"15–25","effect":"Fatigue"},{"rate":"10–20","effect":"Back pain"},{"rate":"10–15","effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL1201828","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eculizumab binds to C5, a key component of the complement cascade, preventing its cleavage into C5a and C5b. This blocks the formation of the terminal complement complex (C5b-9, also called the membrane attack complex), which is responsible for destroying cells in complement-mediated diseases. By inhibiting this final step of the complement pathway, eculizumab reduces hemolysis and inflammation in conditions driven by complement activation.","oneSentence":"Eculizumab is a monoclonal antibody that blocks complement protein C5, preventing the formation of the membrane attack complex and reducing complement-mediated cell destruction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:03.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Paroxysmal nocturnal hemoglobinuria (PNH)"},{"name":"Atypical hemolytic uremic syndrome (aHUS)"},{"name":"Generalized myasthenia gravis (gMG)"},{"name":"Neuromyelitis optica spectrum disorder (NMOSD)"}]},"trialDetails":[{"nctId":"NCT07010302","phase":"PHASE4","title":"Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-05","conditions":"NMOSD","enrollment":540},{"nctId":"NCT05982938","phase":"","title":"Danicopan Early Access Program","status":"AVAILABLE","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis","enrollment":""},{"nctId":"NCT05646563","phase":"PHASE2","title":"Study of NM8074 in Adult PNH Patients with Inadequate Response to Soliris","status":"NOT_YET_RECRUITING","sponsor":"NovelMed Therapeutics","startDate":"2026-01","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":12},{"nctId":"NCT04058158","phase":"PHASE3","title":"A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2019-08-07","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":50},{"nctId":"NCT05726916","phase":"PHASE3","title":"Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-11-09","conditions":"Hypertensive Emergency-associated Hemolytic Uremic Syndrome","enrollment":66},{"nctId":"NCT05863442","phase":"PHASE1","title":"Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants","status":"UNKNOWN","sponsor":"Turgut Ardika PTY LTD","startDate":"2023-04-10","conditions":"Healthy","enrollment":120},{"nctId":"NCT04671810","phase":"","title":"Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2019-06-13","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":44},{"nctId":"NCT04749810","phase":"","title":"Observational Study of Elizaria® in aHUS Patients","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2019-12-19","conditions":"Atypical Hemolytic Uremic Syndrome, aHUS","enrollment":50},{"nctId":"NCT04802083","phase":"","title":"COVID-19 Soliris Expanded Access Protocol","status":"NO_LONGER_AVAILABLE","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"","conditions":"Covid19","enrollment":""},{"nctId":"NCT04463056","phase":"PHASE3","title":"Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2017-11-29","conditions":"Paroxysmal Nocturnal Hemoglobinuria, Marchiafava-Micheli Syndrome, Paroxysmal Hemoglobinuria","enrollment":32},{"nctId":"NCT04355494","phase":"","title":"SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"","conditions":"COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)","enrollment":""},{"nctId":"NCT04060264","phase":"PHASE3","title":"Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"COMPLETED","sponsor":"Biocad","startDate":"2019-04-04","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":28},{"nctId":"NCT04027803","phase":"PHASE1","title":"Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®","status":"COMPLETED","sponsor":"Biocad","startDate":"2018-09-21","conditions":"Healthy Subjects","enrollment":78},{"nctId":"NCT03722329","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2018-11-13","conditions":"Healthy","enrollment":240},{"nctId":"NCT02614898","phase":"","title":"Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2015-11-04","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":67},{"nctId":"NCT02205541","phase":"PHASE3","title":"Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2015-06","conditions":"Hemolytic Uremic Syndrome of Childhood","enrollment":100},{"nctId":"NCT01221181","phase":"PHASE1","title":"Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2010-07","conditions":"Dense Deposit Disease, Membranoproliferative Glomerulonephritis","enrollment":6},{"nctId":"NCT00867932","phase":"PHASE4","title":"Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2009-10-02","conditions":"Hemoglobinuria, Paroxysmal","enrollment":7},{"nctId":"NCT01410916","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2011-07","conditions":"Shiga-like Toxin-producing Escherichia Coli","enrollment":198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Eculizumab (Soliris®)","genericName":"Eculizumab (Soliris®)","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eculizumab is a monoclonal antibody that blocks complement protein C5, preventing the formation of the membrane attack complex and reducing complement-mediated cell destruction. Used for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Generalized myasthenia gravis (gMG).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}